CDK4/6 inhibitor therapy in HR+/ERBB2- metastatic breast cancer
The duration of prior CDK4/6 inhibitor therapy and the presence of visceral involvement are key factors associated with survival in HR+/ERBB2- metastatic breast cancer patients
Day: April 2, 2025